Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti-CD5 monoclonal antibody (antLCD5 IC), with and without concomitant methotrexate andor azathioprine, in the treatment of rheumatoid arthritis (RA).. Results. Using composite criteria, response rates were 5 0 4 8 % at 1 month and 22-25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment-associated adverse effects were common but resolved rapidly without sequelae.Conclusion. These findings suggest activity of anti-CDS IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.